Advertisement

U.S. Markets closed

S&P Futures
5,888.00
-8.25(-0.14%)
Dow Futures
43,134.00
-43.00(-0.10%)
Nasdaq Futures
20,472.75
-46.75(-0.23%)
Russell 2000 Futures
2,250.70
-4.80(-0.21%)
Crude Oil
70.27
-0.29(-0.41%)
Gold
2,743.70
+4.80(+0.18%)

BioNTech SE (22UA.BE)

Berlin - Berlin Delayed Price. Currency in EUR

102.90

-1.10

(-1.06%)

At close: 06:53PM CEST

All

Benzinga
FDA Presses Clinical Hold Button For BioNTech's Partner Late-Stage Trial Of Investigational Lung Cancer Treatment
BioNTech SE (NASDAQ:BNTX) has been notified by its partner, OncoC4 Inc., that the FDA has imposed a partial clinical hold on its Phase 3 PRESERVE-003 trial. The open-label, randomized study evaluates BNT316/ONC-392 (gotistobart) as a monotherapy in patients with metastatic non-small cell lung cancer (NSCLC) who have previously progressed after PD-(L)1-inhibitor treatment. Also Read: Google DeepMind, BioNtech Unveil AI Lab Assistants To Revolutionize Scientific Research. Varying outcomes between
Clinical Trials Arena
FDA clamps partial hold on Phase III trial of BioNTech & OncoC4’s NSCLC therapy
A partial clinical hold was placed on the registrational trial after results showed variance between squamous and non-squamous NSCLC patient responses.